Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00327015 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,306
- Enrollment target
NCT00327015 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 1,306 participants.
The verdict
NCT00327015, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,306 participants
- Enrollment target
Study Summary
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Saxagliptin
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,306 participants |
| Start Date | 2006-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00327015
The ClinicalTrials.gov registry entry for NCT00327015 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00327015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00327015 about?
NCT00327015 is a clinical study titled "A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise". The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
What is the current status of trial NCT00327015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,306 participants. The study started on 2006-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00327015?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Saxagliptin (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00327015?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.